Announcement

Collapse
1 of 2 < >

Scheduled Update

ATTN: The forums will be down part of the day of March 31 for a scheduled update.
2 of 2 < >

Attn: Anyone Who Requested Registration and never got a response.

We normally get back to people on registration requests within a few business days. If you don't hear back from us within a week it may be because we're having difficulty with your email address. If you included your username in your request we've probably registered you already and just can't send you the information. You can give us a call at 1-877-693-7939 between the hours of 8am-4am Pacific time. We'll have your information set aside to give to you in the event attempts to send to your email didn't work.
See more
See less

NHS UK Individual Funding Requests, unproven treatments - consultation by 15 Jan 2017

Collapse
X
  • Filter
  • Time
  • Show
Clear All
new posts

  • NHS UK Individual Funding Requests, unproven treatments - consultation by 15 Jan 2017

    'Consultation Guide on Commissioning Policies: Funding of Treatment outside of Clinical Commissioning Policy or Mandated NICE Guidance - A. In-year service development, B. Individual Funding Requests, C. Funding for experimental and unproven treatments, D. Continuing funding after clinical trials

    https://www.engage.england.nhs.uk/consultation/af642939 Overview

    When first established, NHS England published a set of a set of so-called 'generic policies' to guide its decision-making for all directly commissioned services. They were called 'generic policies' as they applied to all NHS England's commissioning responsibility, rather than being service-specific. Over the last three years, most of these policies have been covered in other existing comprehensive policy documents.

    Four areas still require stand-alone policies, and they are the focus of this consultation.
    The four areas are: in-year service developments, individual funding requests (IFR), funding for experimental and unproven treatments, and continuing funding after clinical trials.

    We welcome views from stakeholders, the public and patients on this revised set of four distinct policies.'
    Paediatric ocular rosacea ~ primum non nocere
Working...
X